dissemination – Page 47 – Communicable Diseases Research

Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial

일반 인구에서 SARS-CoV-2 감시를 위한 4가지 다른 전략의 효과 및 비용 효율성(CoV-Surv 연구): 클러스터 무작위 2인자 통제 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-082022-09-01
Journal: Trials [Category] MERS, 임상, 진단, 치료기술, 치료제,

Misinformation about COVID-19: evidence for differential latent profiles and a strong association with trust in science

Research Article

Published on 2021-01-072022-10-28
Journal: BMC Public Health [Category] COVID-19,

A novel type of colistin resistance genes selected from random sequence space

무작위 서열 공간에서 선택된 새로운 유형의 콜리스틴 내성 유전자

Research Article

Published on 2021-01-072022-09-06
Journal: PLoS Genetics [Category] Communicable Disease,

[키워드] absence activating Activation activity addition Analysis antibiotic Antibiotic resistance antibiotic treatments auxiliary Bacteria Cell cell envelope chimeric clinical isolates colistin d e novo de novo de novo gene described determinant determine dissemination DNA DNA sequence DNA sequences domain dominant E . coli Escherichia coli Evolution examined example expand expressed expression generate growth growth defects idea in vivo Interaction isolate kinase kinases limit lipopolysaccharide low expression levels mechanism Modification modifications non-coding DNA non-coding region non-coding regions Open reading frame open reading frames Pathogens peptide peptides provided random Randomly resistance gene resistance genes selected sequence Spread subsequent substrate Support Surveillance the cell transfer transmembrane domain Treatment variant
[DOI] 10.1371/journal.pgen.1009227 PMC 바로가기 [Article Type] Research Article

A structured summary of a study protocol for a multi-center, randomized controlled trial (RCT) of COVID-19 prevention with Kampo medicines (Integrative Management in Japan for Epidemic Disease by prophylactic study: IMJEDI P1 study)

Kampo 의약품을 사용한 COVID-19 예방에 대한 다기관, 무작위 대조 시험(RCT) 연구 프로토콜의 구조화된 요약(예방 연구에 의한 전염병에 대한 일본의 통합 관리: IMJEDI P1 연구)

Letter

Published on 2021-01-062022-08-31
Journal: Trials [Category] MERS, 임상, 치료제,

[키워드] 1:1 administration age allergic Analysis appearance Arm ARMS assumed Asymptomatic balancing Blinding body temperature calculated capture cardiovascular disease Chain Reaction clinical clinical trials cloud condition Control control group cough COVID-19 diabetes disappearance dissemination doctor dosage dropout rate drug edema effective element Endpoint exclusion criteria failure Fever Final final analysis final analysis) Frequency group hands healthy history hospital Hospitalization hypertension hypokalaemia Hypothesis ICU Immunosuppressant immunosuppressants incidence of COVID-19 incidence rate incidence rates include inclusion criteria Infection infection rate Inflammation interim analysis interstitial pneumonia intervention group investigator Japan Japanese Kampo Kampo medicines liver dysfunction lung malaise management mechanical ventilation Medicine number numbness objective observation period oral administration oral administration) outcome package parallel-group participant Patient PCR PCR positive per day Period pharmaceutical Placebo placebo group Placebo tablets positive result power power of 80% pregnant Prevent Prophylactic prophylactic study protocol randomised Randomized Randomized controlled trial RCT receive recruited Registered Registration registry required Research respiratory respiratory diseases respiratory inflammation risk factor Risk factors Safety Sample size SARS-CoV-2 RNA secondary Secondary outcomes Shock Shortness of breath significantly skin rash sputum study drug study period Study protocol supplementary material Symptom Symptoms symptoms of COVID-19 Tablet Taking Taste the placebo group Trial Trial registration Two-arm university upper respiratory verification Viral viral infection Vital website
[DOI] 10.1186/s13063-020-04939-2 PMC 바로가기 [Article Type] Letter

Rehabilitation Exercise and psycholoGical support After covid-19 InfectioN’ (REGAIN): a structured summary of a study protocol for a randomised controlled trial

재활 운동 및 심리적 지원 After covid-19 Infection'(REGAIN): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-062022-09-10
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 age allocation concealment anticipated anxiety symptoms assessment automatically baseline Bengali best blind Blinding Care clinical clinically Cognitive function Complete computer-generated Controlled trial COVID-19 COVID-19 infection Critical care current death defined depressive determine dissemination Dyspnoea eight element email engage Engagement English exclusion criteria exercise Group allocation Health health economic evaluation health problems hospital hospital care hospital discharge include Informed consent life mental health mental health problem mental health problems NHS number objective Online outcome parallel group participant performed physical physical activity Physical health Post-traumatic stress disorder Practitioner Primary outcome profile protocol psychological support PTSD Quality of life questionnaire randomisation randomised randomised controlled trial rehabilitation Rehabilitation Exercise reported resource Sample size secondary Secondary outcomes sequence Standard status stratified Study protocol Support supported symptom severity Treatment Urdu usual care utility ventilatory ventilatory support Version web-based system website
[DOI] 10.1186/s13063-020-04978-9 PMC 바로가기 [Article Type] Letter

Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial

COVID-19(COVID-AT)로 인한 급성 호흡 곤란 증후군 환자에서 동종 간엽 기질 세포의 효능을 평가하기 위한 이중 맹검, 무작위, 대조 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-062022-09-10
Journal: Trials [Category] MERS, 바이오마커, 임상, 치료제,

[키워드] 1:1 24 hours 7-point ordinal scale acute respiratory distress acute respiratory distress syndrome Administered administration Admission Adult patient Adult patients Adverse Adverse drug reactions AEs age All trial participants all-cause mortality allergy Allogeneic ARDS assessment assigned baseline Biomarker blinded Blinding C-reactive protein carcinoma carcinoma in situ carried cellular chain change childbearing potential Chloroquine Clinical practice clinical status clinical trial coagulation test coagulation tests conducted Control control arm Course COVID COVID-19 CRF criteria CT scan cumulative incidence current Cytokines D-dimer Day death described determined by Diagnosis disease dissemination double-blind drug Duration ECMO Efficacy Efficacy and safety element eligible End endpoints enrolment EudraCT evaluate evaluate the effect event exclusion criteria Extracorporeal extracorporeal membrane oxygenation failure ferritin fibrosis FiO2 form GRADE grade 3 greater Haemodialysis handling hemofiltration history hospital Hospitalization hydroxy ICU ICU admission IMPROVE include inclusion criteria Informed consent intravenous Intravenous administration intravenous dose intubation Invasive mechanical ventilation invasive ventilation investigational medicinal product involved laboratory confirmation laboratory-confirmed SARS-CoV-2 infection lactation LDH less Level Local Lopinavir Lopinavir/ritonavir lung disorder lymphocyte marker Mechanical mechanical ventilation Medicine Medicines Mesenchymal stromal cells moderate to severe Mortality MSC negative pregnancy test neoplasm neutrophil neutrophil counts Non-invasive number objective occur off-label opinion Ordinal Scale organ oropharyngeal swab oropharyngeal swabs Other outcome oxygen oxygen saturation Oxygen therapy PaO2 PaO2/FiO2 ratio parameters participant Patient PCR percentage Placebo polymerase chain reaction Pregnancy primary endpoint product Production profile progression protocol Pulmonary embolism pulmonary fibrosis Pulmonary function tests randomised randomised controlled trial randomization Randomized Randomly Rapid antigen tests reaction receive recruitment Registered Remdesivir report respiratory Respiratory distress syndrome Resuscitation Ritonavir SAEs Sample size SARS-COV-2 infection secondary Secondary endpoints Sequential Organ Failure Assessment Serious Adverse Events SOFA Spain specificity specimen Sponsor Standard of care status stromal cell stromal cells Study protocol subpopulations supplemental oxygen supplementary material syndrome the cell the disease the patient the primary endpoint the WHO time Tocilizumab Tolerability Treatment treatment arm treatment for COVID-19 treatment group Treatment protocol Trial trial participant Trial registration unit website women worldwide pandemic written consent
[DOI] 10.1186/s13063-020-04964-1 PMC 바로가기 [Article Type] Letter

Knowledge, attitude and perception of Pakistanis towards COVID-19; a large cross-sectional survey

Research Article

Published on 2021-01-052022-10-28
Journal: BMC Public Health [Category] COVID-19, MERS,

[키워드] adequate knowledge age Analysis analyzed assigned Attitude Characteristics Chi-square conducted coronavirus country COVID-19 COVID-19 case cross-sectional survey demonstrated Descriptive statistics determine dissemination educational status evaluate facilitate Factor female gender genders General population group groups Health healthcare help identify Infection information Intervention knowledge Misconceptions novel outbreak Pakistan Pakistanis pandemic participant participated Perception predictor Prevent protocol questionnaire regression analysis Result Safe Significant social isolation socio-demographic spread of COVID-19 SPSS supplementary material was used widespread
[DOI] 10.1186/s12889-020-10083-y PMC 바로가기 [Article Type] Research Article

The efficacy and safety of Ivermectin in patients with mild and moderate COVID-19: A structured summary of a study protocol for a randomized controlled trial

경증 및 중등도 COVID-19 환자에서 이버멕틴의 효능 및 안전성: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-01-042022-09-10
Journal: Trials [Category] 임상, 치료제,

[키워드] 1:1 ACE inhibitor ACE inhibitors acute respiratory syndrome Adverse drug reaction Adverse drug reactions AIDS allergy anticipated Anticoagulant Anticoagulants Asthma Bandar Abbas Blinding Breastfeeding Captopril chest X-ray clinical clinical symptom Clinical symptoms clinical trial clinical trials company Computed tomography Confirmed Control control group control groups Controlled trial COVID-19 COVID-19 symptom criteria Critical CXR Department discharge Diseases dissemination dose Drug allergy education Efficacy and safety element evaluate exclusion criteria FIVE France group groups history Hospital stay Hospitalization Hospitalization Mechanical ventilation hydroxychloroquine sulfate ICU admission incidence include inclusion criteria India Infection Informed consent Inpatients Interferon beta-1a intervention group Iran Ivermectin Kidney disease liver loiasis Lopinavir Lopinavir/ritonavir mechanical ventilation Mild mild COVID-19 symptom mild COVID-19 symptoms mild pneumonia Ministry of Health moderate Moderate COVID-19 moderately severe COVID-19 MSD number objective Open-label Other outcome Outpatient outpatients parallel-group participant Patient patients patients with moderate PCR pharmaceutical Pharmaceutical Company Phase 3 Pneumonia Pregnancy Primary outcome Primary outcomes protocol random randomization Randomized Randomized controlled trial receive regimen Registered registration date registration number registry respiratory Ritonavir routine care Sample size secondary outcome selected Seven Severe acute respiratory syndrome single dose single-center standard treatment status Study protocol subsequent supplementary material table the patient Treatment treatment group Trial registration twice a day two group two groups underlying diseases Version Warfarin website weight
[DOI] 10.1186/s13063-020-04988-7 PMC 바로가기 [Article Type] Letter

Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial

중등도에서 중증의 COVID-19(NACOVID) 치료를 위한 nitazoxanide + atazanavir/ritonavir의 효능 및 안전성: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Comparative Study

Published on 2021-01-042022-09-10
Journal: Trials [Category] 신약개발, 임상, 치료제,

[키워드] 1:1 24 hour 24 hours achievement addition Administered African age allocation anticipated antiretroviral drugs antiviral activity approval Atazanavir atazanavir/ritonavir Blinding Care clinical Clinical improvement Clinical management Comorbidities confirmation Control control group COVID-19 COVID-19 diagnosis COVID-19 infection criteria defined determined by diagnosed Diagnosis discharge dissemination drug Drug administration drugs Efficacy and safety element eliminated enrolment exclusion criteria food Food and Drug Administration Gender group hospital hypersensitivity include inclusion criteria Infectious diseases information initiation of treatment Interaction intervention group Isolation lactating mechanical ventilation medication moderate moderate to severe multicentre Nasopharyngeal swab negativity Nigeria nitazoxanide number objective Ogun once daily Open-label open-label trial Ordinal Scale outcome measure Pan Pan African Clinical Trials Registry participant Patient PCR PCR test Phase 2 physician polymerase chain polymerase chain reaction positive pregnant Proportion of participant protocol quantified randomisation randomised randomised controlled trial receive receiving recruited REDCap Registered registry reported Ritonavir RT-PCR Saliva Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR SARS-CoV-2 polymerase chain reaction SARS-CoV-2 viral load secondary care sequence severe COVID-19 specialist Standard Standard of care state Stratification Study protocol supplementary material symptomatic Teaching Temporal the WHO time Treatment Trial Trial registration university Viral Viral load website working
[DOI] 10.1186/s13063-020-04987-8 PMC 바로가기 [Article Type] Comparative Study

Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)

입원한 COVID-19 환자의 중증 SARS-CoV-2 감염 예방을 위한 재조합 인간 C1 에스테라제 억제제(conestat alfa): 무작위, 병렬 그룹, 공개 라벨, 다중 센터에 대한 연구 프로토콜의 구조화된 요약 파일럿 시험(PROTECT-COVID-19)

Letter

Published on 2021-01-042022-09-10
Journal: Trials [Category] 임상,

[키워드] 24 hour 24 hours Activation activities acute lung injury addition adjusted Administered administration allergy Antibiotics anticipated anticoagulation arterial Arterial hypertension Basel Blinding BMI Brazil Breast Breast feeding breathing ambient air C-reactive protein C1 esterase inhibitor cardiovascular disease Caregivers changes in Chest Child-Pugh score chronic chronic pulmonary disease chronic renal disease cirrhosis class clinical Clinical improvement clinical trial comparator comparator Patients complement complement system completion conducted Conestat alfa Contact contact activation system contraindication control group Corticosteroids COVID-19 COVID-19 patient CT scan death defined discharge disease disease severity dissemination drug Duration Efficacy and safety element eligibility enrolment evidence of experimental arm family members FIVE followed by history hospital Hospitalization hospitalized patient hypertension ICU IL-6 inhibitor IL-6R improvement Incapacity include inclusion criteria individual Infection inflammatory cascade inflammatory cascades inflammatory proteins inhibitor Interactive Web Response System interim analysis Intravenous injection invasive invasive or non-invasive ventilation investigator-initiated investigators kallikrein kinin system laboratory parameter Liver cirrhosis Local Lung injury mechanical ventilation non-invasive ventilation not blinded number obesity objective Open-label open-label trial Ordinal Scale outcome outcome assessor outcome assessors oxygen oxygen saturation pandemic PaO parallel-group participant Participants Participation Patient performed Pregnancy primary endpoint progression proportion protocol pulmonary disease pulmonary involvement randomised randomization Randomized randomized trial receive recombinant recruited recruitment Registered Remdesivir renal renal disease required risk factor Sample size SARS-COV-2 infection SARS-CoV-2 pandemic scale screened secondary Secondary outcomes severe COVID-19 severe SARS-CoV-2 Standard of care status Study protocol subject supplemental oxygen supplementary material suspicion Switzerland Symptom the SARS-CoV-2 the WHO their family members Tocilizumab Treatment treatment arm Trial Two interim analyses Two interim analysis virological clearance website WHO WHO ordinal scale with COVID-19 X-ray
[DOI] 10.1186/s13063-020-04976-x PMC 바로가기 [Article Type] Letter